iBio IBIO Stock News

In several past posts, I informed readers that when iBio Inc (NYSEAMERICAN: IBIO) releases updates surrounding its work with regard to the novel coronavirus, the stock would likely see tremendous gains. Well, they have and it is. The stock is trading up more than 30% early in the premarket after the company announced an update with regard to the development of the COVID-19 vaccine. Here’s the scoop:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Soars On COVID-19 Update

In a press release issued early this morning, iBio said that it is making progress in the development of vaccine candidates for preventing infection from the SARS-CoV-2 virus. This is the virus that causes the coronavirus disease.

In the release, IBIO said that it has created its SARS-CoV-2 Virus-LIke Particle. This was created based on constructs in just weeks using its FastPharming System to produce the nanoparticules used.

The company said that the manufacturing platform provides for rapid development of research quantities of the product. It is also highly scalable for producing doses for both clinical and commercial use.

The company went on to explain that it has filed four provisional patent applications in the United States surrounding its platform and other technologies for the prevention and treatment of infections with the SARS-CoV-2 virus.

In a statement, Tom Isett, Co-Chairman and CEO at IBIO, had the following to offer:

We are pleased with both the speed of our development activities and the quality of the VLPs our technology is yielding in practice. The tightly controlled particle size allows for uniform antigen display, which should translate to a consistent dose response and a highly efficient production process, facilitating a ramp-up to tens of millions of doses if we are successful in the clinic.

The above statement was followed up by Dr. Sylvain Marcel, VP of Protein Expression Science at IBIO. Here’s what he had to say:

I am optimistic about the potential of our COVID-19 vaccine program. In addition to our core VLP production capabilities, we are coating VLPs with oligomannose so that their glycosylation profile closely resembles that of naturally occurring SARS-CoV-2 viruses. This may allow for more efficient uptake of the vaccine by human antigen presenting cells via their mannose receptors. If so, it could result in enhanced protection against SARS-CoV-2. We look forward to providing further updates on our progress as developments unfold.

Serious Gains Are Likely Ahead

While today’s news has already lead to an influx of buying iBio stock, today’s gains are far from all that we’re likely to see. At the end of the day, the company has several strategic advantages.

First and foremost, the company’s partner in this space is CC Pharming. CC Pharming has already developed an antivirus for SARS, a cousin virus to the Wuhan coronavirus. Beyond this experience, the FastPharming System and FastPharming Facility at IBIO give the company the advantage of quick production and manufacturing. This is key in times of a pandemic.

Due to these strategic advantages, IBIO likely has plenty more room to run as the company continues to work toward the development of a vaccine. There’s also a good chance that other companies that may develop a vaccine first will want to work with iBio due to their capabilities when it comes to speed of manufacturing.

All in all, IBIO has a lot going for it and investors know it!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.